Howard I. Scher, MD

Articles

Dr. Scher on Promise of Liquid Biopsies in Prostate Cancer

February 8th 2017

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

Dr. Scher on Predicting Sensitivity to Treatment for mCRPC

November 18th 2016

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Dr. Scher on Key Findings From the COU-AA-302 Trial

May 13th 2013

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.

Dr. Scher on Corticosteroids and Enzalutamide in mCRPC

February 15th 2013

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

Dr. Scher on Using the Circulating Tumor Cells Test

June 30th 2011

Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test

Dr. Scher on the Future of the Circulating Tumor Cell Test

June 28th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Dr. Scher on Circulating Tumor Cells in Prostate Cancer

June 27th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

Dr. Scher Discusses Circulating Tumor Cells

June 23rd 2011

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells